ライフサイエンスコーパス: smoking history

1 f colonoscopy, age, sex, race/ethnicity, and smoking history.

2 for age, sex, body mass, diagnosis year, and smoking history.

3 of age and with greater than a 15 pack-year smoking history.

4 re in young smokers, with a relatively short smoking history.

5 ho are active smokers) correlated with their smoking history.

6 type, anti-CMV IgG positivity, age, sex, and smoking history.

7 he best outcomes occur when the donor has no smoking history.

8 rease in miRNA abundance was associated with smoking history.

9 nset, despite their young age and paucity of smoking history.

10 tial transplant from a donor with a negative smoking history.

11 emor, a history of constipation, and lack of smoking history.

12 er prognosis and survival than those without smoking history.

13 of vimentin and fibronectin, irrespective of smoking history.

14 ith lung cancer risk independent of reported smoking history.

15 = 0.039) compared with participants with no smoking history.

16 ity, education, childhood family income, and smoking history.

17 elationships between CT findings and age and smoking history.

18 ure include larger diameter, female sex, and smoking history.

19 e compared after adjusting for age, sex, and smoking history.

20 were reviewed for pathology, BC therapy, and smoking history.

21 and 24 controls matched for age, gender, and smoking history.

22 ation), unmarried status, HIV infection, and smoking history.

23 isk factor for AAA in women with significant smoking history.

24 lts were unaffected by neuroleptic status or smoking history.

25 or potential confounders, including detailed smoking history.

26 seemed to be more pronounced in women with a smoking history.

27 nce persisted after covarying for height and smoking history.

28 king cessation are largely affected by their smoking history.

29 2.4-22.4, p < 0.001) and was independent of smoking history.

30 questionnaires were used to collect detailed smoking history.

31 and lung function in older adults differs by smoking history.

32 ); 58 patients were male, and 47 (65%) had a smoking history.

33 ositive, and (3) reporting minimal or remote smoking history.

34 lood pressure, diastolic blood pressure, and smoking history.

35 G sites, even among individuals with a short smoking history.

36 re frequently observed in LUAD patients with smoking history.

37 g high-risk individuals according to age and smoking history.

38 with breast cancer and those with long-term smoking history.

39 for stage, human papillomavirus status, and smoking history.

40 obstruction (a COPD hallmark) in relation to smoking history.

41 send deprivation scores, alcohol intake, and smoking history.

42 toms as well as risk factors such as age and smoking history.

43 wo diagnostic breathing tests, and cigarette smoking history.

44 0 (39%) used lungs from donors with positive smoking histories.

45 risk = 3.0 if age >47 years, P = 0.032) and smoking history (2% increase in risk/pack-year of smokin

46 hole blood of 48 individuals with a detailed smoking history (24 never-smokers, 16 smokers, and 8 ex-

47 By smoking history, 29 subjects were identified as smokers,

48 0,131 patients; age range, 45-81 yr; average smoking history, 44.3 pack-years), we evaluated spiromet

49 Among patients with available quantified smoking history, 48% were age 55-74 years and smoked 30-

50 developing IH were history of AS (87.5%) and smoking history (75%).

51 olization material used, microcatheter type, smoking history, active tobacco use, and other risk fact

52 Pattern of medication use, smoking history, age, body mass index (BMI), and health

53 ible for lung cancer screening (30 pack-year smoking history, ages 55-74 years, for the reference sce

54 odds ratios (ORs) and 95% CIs, adjusting for smoking history, alcohol consumption, and detection of H

55 race/ethnicity, neutrophil-lymphocyte ratio, smoking history, alcohol use, and Charlson Comorbidity S

56 e, race, body mass index, physical activity, smoking history, alcohol use, history of myocardial infa

57 sex, education, income level, occupation, or smoking history among the groups (P >0.05).

58 al and biological features such as age, sex, smoking history, anatomic location, histological type an

59 nalyzed for interactions between allergy and smoking histories and inherited variants in 5 establishe

60 We obtained smoking histories and measured urine 4-(methylnitrosamin

61 Cumulative tobacco smoking histories and spirometry were obtained at ages 1

62 , young African American DM patients with no smoking history and a BMI </=25 are at reduced risk, and

63 ocial history was notable for a 20-pack-year smoking history and a recent relocation to a neighborhoo

64 into distinct clusters that correlated with smoking history and alterations of reported lung adenoca

65 f age 55 to 80 years who have a 30 pack-year smoking history and are currently smoking or have quit w

66 index for AN using age, sex, family history, smoking history and BMI was found to be of limited discr

67 , family history of colorectal cancer (CRC), smoking history and body mass index (BMI) may be useful

68 Stratified analyses by smoking history and cancer subtypes were also performed.

69 Smoking history and childhood-onset persistent asthma we

70 ed into those with and without a significant smoking history and compared with patients with COPD, th

71 aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within

72 aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within

73 ed considerably more active smokers than did smoking history and detected a high prevalence of second

74 g for known risk factors, including detailed smoking history and dietary factors, participants with a

75 Additional stratified analyses by smoking history and lung cancer subtypes were performed

76 0.05) after adjustment for age, sex, height, smoking history and medication.

77 er smokers, each with a minimum 30-pack-year smoking history and mild or no abnormalities at PFT, und

78 er risk, including sex, variables related to smoking history and nicotine addiction, medical history,

79 mpleted a detailed questionnaire on parental smoking history and on putative risk factors for myopia.

80 68 participants completed a questionnaire on smoking history and other risk factors.

81 d the association of LTBI with self-reported smoking history and smoking intensity in multivariable l

82 Cox models assessed the association between smoking history and the primary trial outcome of DFS (ie

83 les were taken at the surgery to confirm the smoking history and to quantify cigarette use.

84 classified according to their self-reported smoking history and urinary cotinine concentration withi

85 nd=0.005) after adjustment for self-reported smoking history and urinary total cotinine.

86 ed 55-80 years with a 30 pack-year cigarette smoking history and, if they are former smokers, those w

87 moker of 30 cigarettes per day (45 pack-year smoking history), and he consumed four standard drinks o

88 Demographic factors, smoking history, and a detailed occupational history, in

89 factors for AAA include older age, male sex, smoking history, and a family history of AAA.

90 alyses (OSAs) with apolipoprotein E alleles, smoking history, and age at onset as stratifying covaria

91 ible to H1N1pdm09 infection, whereas gender, smoking history, and age do not appear to affect AEC sus

92 ones, height, weight, body mass index (BMI), smoking history, and alcohol intake.

93 ation about donor lungs were collected (age, smoking history, and blood gas before lung harvesting).

94 pparent temperature, season, age, race, sex, smoking history, and body mass index as predictors.

95 tified by disease stage, performance status, smoking history, and centre, block size 10) to receive o

96 Baseline data included demographics, smoking history, and computed tomography emphysema.

97 ischemic attack or cerebrovascular accident, smoking history, and creatinine clearance (hemoglobin le

98 Reported sputum production, smoking history, and current cigarette consumption stron

99 Assignment to exemestane, having a smoking history, and current employment also were signif

100 med by statistically adjusting atopy status, smoking history, and disease duration.

101 tions while adjusting for maternal age, sex, smoking history, and educational attainment.

102 were adjusted for age, sex, alcohol intake, smoking history, and educational attainment.

103 0 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor ex

104 She had no smoking history, and her body mass index was normal (23.

105 ndependently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the t

106 ccounting for age, serum cholesterol levels, smoking history, and hypertensive status; adjusted predi

107 fit extended across age, performance status, smoking history, and induction response (stable disease

108 xposed to asbestos, after adjusting for age, smoking history, and intervention arm.

109 uded self-reported demographics, medical and smoking history, and lung cancer-specific and all-cause

110 of patient survival independent of age, sex, smoking history, and mutational load.

111 iological and severity-of-illness variables, smoking history, and number of concomitant medications),

112 males, adjusting for confounders (area, age, smoking history, and number of elder siblings) and also

113 of subgroups defined according to age, sex, smoking history, and risk of lung cancer and performed s

114 body-mass index, current smoking status and smoking history, and severity of airflow limitation.

115 ariety of factors, including a comprehensive smoking history, and submitted toenail samples, from whi

116 ed by knowing the age at disease onset, sex, smoking history, and the presence of HLA-B*4100, DRB1*08

117 010 and analysed retrospectively around age, smoking history, and the use of ICS (including combinati

118 mericans after adjusting for age, sex, race, smoking history, and various disease comorbidities using

119 rain death or circulatory death), bilirubin, smoking history, and whether the liver was split.

120 [aOR], 1.32; 95% CI, 1.18-1.47) and current smoking history (aOR, 1.28; 95% CI, 1.12-1.45), with sig

121 Workers' smoking histories are not measured in many occupational

122 Disease stage and smoking history are often used in current clinical trial

123 lifestyle questionnaire including a detailed smoking history at baseline.

124 for postbronchodilator ventilatory function, smoking history, atopy, and treatment.

125 lling for histopathologic diagnosis, gender, smoking history, baseline forced vital capacity, and 6-m

126 6, after adjustment for age, race/ethnicity, smoking history, benign prostatic hyperplasia, and famil

127 function or as age, sex, chronic conditions, smoking history, blood pressure, body mass index, and ho

128 ing for clinical site, patient age, reported smoking history, body mass index (BMI), diabetes, HIV, a

129 d gender, with no significant differences in smoking history, body mass index, menopausal status, or

130 The patient had a smoking history but had quit smoking 5 years prior to pr

131 ty and lung function is thought to depend on smoking history but most previous research uses self-rep

132 g cancer relative to smokers with comparable smoking history but possessing the lowest tertiles of ur

133 be higher in men than women with comparable smoking histories, but differences were modest; smoking

134 overall, and within demographic, weight, and smoking history categories, and by histological subtype

135 nction by gender, treatment group, and three smoking history categories: sustained quitters, intermit

136 operative Oncology Group performance status, smoking history, centre, and masked pretreatment serum p

137 In multivariable models, smoking history, conditioning with high-dose total body

138 Careful family history, smoking history, consideration of absolute versus catego

139 phocyte engraftment dynamics, lung function, smoking history, corticosteroids, antiviral treatment, v

140 or pool by exclusion of donors with positive smoking histories could compromise survival of patients

141 k [RR], 2.34; 95% CI, 1.55-3.53), or lack of smoking history (current vs never: RR, 0.44; 95% CI, 0.3

142 agnosis (local, regional, or metastatic) and smoking history (current, previous, or nonsmoker).

143 Demographic characteristics, smoking history, depression symptoms, and body mass inde

144 associated with allergy history but not with smoking history despite putative biologic plausibility.

145 tial transplant from a donor with a negative smoking history donor, by analysing all waiting-list reg

146 In a Cox model adjusted for age, sex, and smoking history, drinking 0.5-1.5 drinks per day decreas

147 n of randomized treatment assignments and of smoking history during the study with changes in lung fu

148 Randomisation was stratified by smoking history, ECOG performance status, disease histol

149 factor data (age, sex, race, weight, height, smoking history, education, marital status, diet, alcoho

150 pregnancy BMI in the controls), age, parity, smoking history, educational level, and delivery year.

151 er clinical information (e.g. survival, age, smoking history, etc.) than the images and the correspon

152 pients of lungs from teenaged donors with no smoking history exhibited a higher morbidity and mortali

153 of lungs from heavy smokers (>40 pack-years smoking history) exhibited a significantly higher incide

154 included age, stage, past history of cancer, smoking history, family history of cancer, HRT use, trea

155 ed by geographical variation in gender, age, smoking history, farm exposure, family size and BMI.

156 bjects and further adjusted for age, gender, smoking history, farm exposure, number of older siblings

157 cluding adenocarcinoma histology, absence of smoking history, female sex, and Asian ethnicity.

158 Smoking histories for individual birth cohorts that actu

159 l Health Interview Surveys yielded cigarette smoking histories for the US adult population in 1964-20

160 patients who met USPSTF criteria by age and smoking history for annual chest screening and were foll

161 of a woman with severe COPD, a 50-pack-year smoking history, frequent COPD exacerbations, and recurr

162 udied, largely because obtaining an accurate smoking history from critically ill patients is difficul

163 ich was due to the difficulty of identifying smoking history from search terms.

164 as the duration and location of procedures, smoking history, gender, and age were recorded.

165 -3)), although we were unable to stratify by smoking history; genetically predicted smoking initiatio

166 data from COPDGene (n = 10,131; ages 45-81; smoking history, >/=10 pack-years), we evaluated spirome

167 ts receiving lungs from donors with positive smoking histories had a lower unadjusted hazard of death

168 tice.A 78-year-old woman with a 40-pack-year smoking history has been referred for treatment of advan

169 His 75-pack-year smoking history has resulted in a chronic daily cough an

170 aged between 30 and 60 years with a positive smoking history have a four-fold increased risk for havi

171 Heart recipients with a smoking history have increased risk of developing corona

172 e younger and more likely to be male, have a smoking history, have hyperlipidemia, and have HF with r

173 dependently of ABI, age, male sex, diabetes, smoking history, high body mass index, myocardial infarc

174 roportional hazards models adjusted for age, smoking history, history of diabetes mellitus, and/or se

175 (HR = 2.04), bariatric surgery (HR = 1.78), smoking history (HR = 1.74), liver disease (HR = 1.60),

176 Along with smoking history (ie, less time since smoked), younger ag

177 cy that uses lungs from donors with positive smoking histories improves overall survival of patients

178 k than controls matched for age, gender, and smoking history in developing or having an increased pro

179 The interaction of HLA-DRB1 with smoking history in disease predisposition, along with pr

180 The risk that a positive smoking history in lung donors could adversely affect su

181 uthors adjusted for pack-years from reported smoking history in multivariate analyses, the relative r

182 y, this study revisited the effects of donor smoking history in relation to age on transplant outcome

183 ge, single-center experience, the absence of smoking history in the donor did not result in better lo

184 Clinicians should consider including smoking history in their discussions with patients about

185 Self-reported smoking history included smoking status, duration, inten

186 e response was observed in men regardless of smoking history, including in never-smokers.

187 del estimates that patients who have serious smoking history increase the risk of lung cancer through

188 on HPV status, tumor stage, nodal stage, and smoking history into risk groups with differing risks of

189 for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.0

190 If smoking history is modeled for 20 or 40 pack-years, incr

191 hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced no

192 On the basis of age and smoking history, it is often easy to distinguish between

193 ed to analyze coaxial needle size, age, sex, smoking history, lesion size, use of an automated core b

194 50 years of age, with more than 20 pack-year smoking histories, living in an urban setting, and with

195 naive patients with adenocarcinoma and light smoking histories (< or = 20 pack-years).

196 or older, increased weight, rapid pulse, and smoking history (< or =8 points each).

197 rod performance status (0 vs 1), and tobacco smoking history (<=10 pack-years vs >10 pack-years).

198 001), as were performance status, older age, smoking history, male sex, treatment factors, and stage

199 gingival index scores than age, gender, and smoking history matched controls.

200 ender, alcohol consumption, medical therapy, smoking history, metabolic risk factors, mobilizable iro

201 aged between 30 and 60 years with a positive smoking history might benefit from a screening recommend

202 Amongst women with >=20 pack year smoking history (n = 19,286), 2148 (11.1%) had premature

203 I = 2.1-4.9) of participants who reported no smoking history (n = 887).

204 th cohort decades (1940s to 1980s) and three smoking history (nonsmokers, never-dependent smokers and

205 cancer mortality in high-risk participants (smoking history of >/=30 pack-years) aged 55 to 74 years

206 nefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more be

207 ad been hospitalized for an AECOPD and had a smoking history of >=10 pack-years and one or more exace

208 Patients with a smoking history of </=11 pack years (the median value) t

209 ncer (non-smokers or lifetime smokers with a smoking history of <10 pack-years).

210 40 years or older, had a history of COPD, a smoking history of 10 or more pack-years, a ratio of for

211 vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving

212 itive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-years or less, and negative m

213 ts aged 50-80 years with lung cancer, with a smoking history of 30 pack-years or more, and included b

214 s 41.6+/-17.7% of the predicted value, and a smoking history of 50.6+/-27.4 pack-years.

215 This patient had a smoking history of 80 pack-years, but she had quit smoki

216 rced vital capacity (FVC) of 0.70 or less, a smoking history of at least 10 pack-years, and a score o

217 linical COPD, defined as participants with a smoking history of at least 10 pack-years, FEV1 less tha

218 atients were 40 years of age or older with a smoking history of at least 20 pack-years and a diagnosi

219 atients with COPD aged 40-80 years who had a smoking history of at least 20 pack-years, recruited fro

220 55 through 80 years for ever-smokers with a smoking history of at least 30 pack-years and ex-smokers

221 ymptomatic persons aged 55 to 74 years, with smoking history of at least 30 pack-years.

222 ality in current smokers were evident from a smoking history of less than 10 pack-years, whereas the

223 e overweight, Black, have >=20 pack years of smoking, history of cardiovascular disease, hypertension

224 raphic variation (north vs south), cigarette smoking, history of diabetes, and education, compared wi

225 k included older age, female sex, history of smoking, history of hypertension, overall burden of medi

226 Smoking, history of periodontitis, and type of implant s

227 cceptance of lungs from donors with positive smoking histories on survival and compared it with the e

228 mation is available on the impact of current smoking history on these metabolites.

229 ke may be underestimated in studies based on smoking history only.

230 hyperlipidemia (OR 1.21; 95% CI: 1.14-1.28), smoking history (OR 1.11; 95% CI: 1.05-1.17), and white

231 -1.64); male gender (OR 1.26, CI 1.06-1.50); smoking history (OR 1.20, CI 1.02-1.40); and procedure t

232 However, in multivariable analysis, only smoking history (OR 3.18, 95% CI 1.11-9.06) was associat

233 d a significant association between positive smoking history (OR 3.7, 95%CI 1.61 to 8.50), hypertensi

234 severe pulmonary regurgitation (OR, 9.0) and smoking history (OR, 27.2).

235 sider tumor-level clinical/demographic (e.g. smoking history) or molecular features (e.g. inactivatio

236 itudinal lung function decline in survivors, smoking history, or current smoking status.

237 l survival did not differ based on age, sex, smoking history, or ethnic origin.

238 d menopause, menopausal status at diagnosis, smoking history, or prior use of the oral contraceptive

239 White race and smoking history over 40 pack-years were positively assoc

240 rtension, diabetes, hypercholesterolemia and smoking history (p < 0.0001).

241 creasing patient age (P < .001) and positive smoking history (P = .001) were associated with increase

242 ogate of human papillomavirus) and cigarette smoking history (pack-years) randomly assigned to clinic

243 Gender and smoking history (pack-years) were included as covariates

244 We obtained data on smoking history, perioperative risk factors, and 30-day

245 mily history of myocardial infarction, race, smoking history, physical activity, and quality of life.

246 Adjusted for age, sex, disease duration and smoking history, pRBD was associated with greater sleepi

247 edian body mass index 47 kg/m) self-reported smoking history pre-surgery, and current smoking behavio

248 Sex, histology, skin rash, and smoking history predicted outcome with erlotinib.

249 s to define potential confounders, including smoking history, presence and severity of lung and heart

250 elations persisted after correction for age, smoking history, presence of lung cancer, recent respira

251 year-old man with a 45 pack per year tobacco-smoking history presented with painless gross hematuria

252 A 54-year-old man with a former 15-pack-year smoking history presents with cough and dyspnea.

253 matic subgroup, predictors of mortality were smoking history, previous carotid endarterectomy, hemogl

254 fe, dyspnea, oxygen utilization, hemoglobin, smoking history, quantitative emphysema markers on compu

255 or 6 confounders: age, sex, education level, smoking history, RA severity, and prednisone use.

256 orating tumor staging, treatment status, and smoking history revealed that treatment status had the m

257 confirmed as risk factors for deterioration; smoking history seemed to be protective against VF deter

258 defined by variables such as age, diabetes, smoking history, serum creatine phosphokinase, or electr

259 with education, family income, alcohol use, smoking history, serum levels of cotinine, or C-reactive

260 ignificant changes about lung function test, smoking history, sex and the levels of D-dimer among two

261 Patient variables included smoking history, sex, age, primary site, tumor stage, an

262 reased survival, patients with a significant smoking history should be carefully scrutinized for live

263 The recipients of lungs from donors with a smoking history showed better 5-year survival than recip

264 lity remained after adjustment for cigarette smoking history, social class, body mass index, systolic

265 ncluding age, sex, race, performance status, smoking history, stage, treatment history, and overall s

266 s, including laboratory values, medications, smoking history/status, and postoperative outcomes, were

267 rong predictor of lung cancer independent of smoking history, suggesting that the adverse effects of

268 ally, SS is correlated with current and past smoking histories, systolic blood pressure, HDL levels (

269 onal studies attempt to control for reported smoking histories, the accuracy of self-reported smoking

270 When adjusted for age, sex, diet, and smoking history, the relative risk for AMD decreased 10%

271 splant of lungs from teenaged donors with no smoking history, this study revisited the effects of don

272 n (block size=3) stratified by age, sex, and smoking history to receive 10 mg/kg intravenous durvalum

273 harvesting, and comorbid health conditions (smoking history, type 2 diabetes mellitus, hypertension,

274 carcinogen dose than by using self-reported smoking history, ultimately improving the estimation of

275 who received lungs from donors with negative smoking histories (unadjusted hazard ratio [HR] 1.46, 95

276 nts with intracranial aneurysm (53.8%) had a smoking history vs 163 of 564 patients without intracran

277 Smoking history was associated with attachment loss.

278 Smoking history was collected using questionnaires.

279 A positive smoking history was encountered in 57.5% of cases and in

280 Smoking history was more common (P = .0008) in patients

281 ue eosinophilia, whilst no clear relation to smoking history was observed.

282 Information about smoking history was obtained by questionnaire.

283 Smoking history was obtained from chart review or via te

284 Smoking history was obtained from patients, their surrog

285 A detailed smoking history was obtained.

286 Subgroup analysis by sex and smoking history was performed.

287 Additionally, smoking history was predictive of [50] CAD and sedentary

288 Smoking history was self-reported at baseline; newly dia

289 Detailed lifetime smoking histories were collected by personal interview i

290 l measurements, demographic information, and smoking histories were recorded.

291 and information on participant schooling and smoking history were collected at 23-25 y of age.

292 her body mass index (>/= 25), diabetes, or a smoking history were less likely, to undergo biopsy, adj

293 als matched with respect to age, gender, and smoking history were selected and evaluated for the same

294 lems with lungs from teenaged donors with no smoking history were suggested.

295 and 10 controls matched for age, gender, and smoking history, were chosen to participate in a study e

296 ients with < T4, < N2c, and </= 10 pack-year smoking history who were treated with </= 54 Gy of radia

297 ses on age (+/-5 years), sex, ethnicity, and smoking history, who were recruited from a local multisp

298 here were no interactions for glioma risk of smoking history with any of the risk alleles.

299 All findings were independent of pack-year smoking history with multiple logistic regression analys

300 After results were controlled for age and smoking history, women with at least 1 child had 0.71 ti